European stocks trading in the U.S. moved higher late Thursday morning, with the S&P Europe Select ADR Index climbing 1.24% to 1,928.04. The gain, however, was not evenly spread: biotech names accounted for the biggest swings, with some jumping sharply while others tumbled.
Biotech leads the way, but not for everyone
The index's rise was driven by a handful of smaller health care ADRs. Cellectis, a French gene-editing company, led the pack with a 10.9% surge. Other biopharma names, including DBV Technologies and Autolus Therapeutics, also rose, contributing to the sector's strength.
But the day wasn't uniformly positive. Biodexa Pharmaceuticals slid 19.8%, a reminder that biotech investing can be a two-way street. Such sharp divergences are common among U.S.-listed biotech stocks, where thinner trading volumes and wider bid-ask spreads can amplify price moves. A relatively modest burst of buying or selling can translate into a large percentage change, especially for smaller companies.
For everyday investors, this means that while the index's gain looks broad, the underlying action is concentrated. The performance of a few volatile names can skew the overall picture, so it's worth looking beyond the headline number.
What are ADRs and why do they matter?
American Depositary Receipts (ADRs) are U.S.-traded certificates that represent shares in foreign companies. They allow U.S. investors to buy and sell overseas stocks on American exchanges, in dollars, without dealing with foreign currency or cross-border brokerage accounts. The S&P Europe Select ADR Index tracks a basket of European companies that trade as ADRs, offering a snapshot of how European equities are faring in the U.S. market.
Thursday's move comes amid a broader backdrop of mixed European markets. Earlier in the week, European stocks slipped as oil prices and bond yields pressured risk appetite, as noted in our coverage of that decline. The ADR rebound suggests some investors are stepping back in, though the concentration in biotech suggests it may be more about sector-specific news than a broad shift in sentiment.
What it means for investors
For those holding European ADRs, the index gain is a positive sign, but the volatility in biotech underscores the risks of investing in smaller health care names. These stocks can move dramatically on clinical trial results, regulatory decisions, or even speculative trading, and the wide spreads can make it costly to enter or exit positions.
Investors should also consider the broader European economic picture. Recent data on consumer spending and corporate loan activity have been mixed, with U.S. shoppers keeping up spending and European banks shifting loan risk to investors. These factors can influence how European companies perform, and by extension, their ADRs.
For those looking to diversify internationally, ADRs offer a convenient way to gain exposure to European markets. But as Thursday's action shows, the index can be swayed by a few high-flying or falling stocks. It's important to understand what you're buying and to be prepared for volatility, especially in the biotech sector.
As always, this is not a recommendation to buy or sell any specific stock. Instead, use this as a reminder to review your portfolio's exposure to international markets and to consider whether the risk profile of smaller biotech names fits your investment goals.
